Skip to main content
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. — Investor Relations & Filings

Ticker · VKTX ISIN · US92686J1060 LEI · 529900IVC72YPFA25M37 US Professional, scientific and technical activities
Open in API
Filings indexed 608 across all filing types
Latest filing 2024-07-30 Regulatory Filings
Country US United States of America
Listing US VKTX

About Viking Therapeutics, Inc.

https://vikingtherapeutics.com/

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's pipeline is centered on small molecule drug candidates designed to address these conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-07-30 English
Regulatory Filings 2024
Regulatory Filings
2024-07-30 English
10-Q
Interim / Quarterly Report Q2 2024
2024-07-24 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 24, 2024, reporting the issuance of a press release with financial results for the second quarter ended June 30, 2024. The text states that the press release is furnished as an exhibit and incorporated by reference, indicating this document itself is a current report announcing the earnings release rather than the earnings release document itself. The document length is 3880 characters, which is relatively short and consistent with an announcement rather than a full earnings report. Therefore, this filing is best classified as an Earnings Release (ER) announcement within a Form 8-K context, which aligns with the ER category as the initial announcement of quarterly financial results.
2024-07-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text specifically mentions a press release announcing results from a Phase 2b study, furnished as an exhibit. There are no detailed financial statements or comprehensive financial data included in the text. The document length is 3470 characters, which is relatively short and primarily serves as an announcement of the press release rather than the full report itself. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 8-K filings that announce events or press releases.
2024-06-04 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Viking Therapeutics, Inc. It reports on the results of the 2024 Annual Meeting of Stockholders held on May 21, 2024, including voting results on various proposals such as election of directors, ratification of auditors, advisory approval of executive compensation, and approval of equity incentive and employee stock purchase plans. The document primarily provides official voting results from the shareholder meeting. It does not contain full financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement or solicitation material but reports the outcomes of votes. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7698 characters) and content confirm it is a detailed voting results report rather than a brief announcement or a proxy solicitation. Confidence is high given the clear presence of voting results and the nature of Form 8-K Item 5.07 disclosures.
2024-05-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.